GRAL Stock — GRAIL, Inc.

GRAIL, Inc. (GRAL)

Updated October 16, 2026.

GRAL is a Stock. Total return is 762.4% over the past 2.3 years, 717.2 points ahead of SPY at 45.2%.

GRAIL, Inc. is a commercial-stage healthcare company that develops multi-cancer early detection testing and services, including its Galleri screening test for asymptomatic individuals over 50, diagnostic aids to support cancer evaluation, and a precision oncology portfolio based on methylation-based platforms for disease monitoring and risk assessment. The company does not currently have an established distribution schedule. GRAIL appeals to investors seeking exposure to early-stage healthcare innovation rather than current income.

GRAL performance versus SPY

Price and return data through 2026-10-16.

Total return is 762.4% over the past 2.3 years, 717.2 points ahead of SPY at 45.2%. Over the past year its total return — price change plus distributions reinvested — is 36.3%. Its deepest 1-year drawdown was 62.9%.

GRAL key facts

Asset type

Stock

Asset class

Equity

Inception date

06/12/2024

Distribution frequency

None

Last close

$117.81 (as of 2026-10-16)

Market cap

$5,262,129,028

Average volume

1304242.0

Beta

2.838

Payout ratio

0.0%

EPS

$-9.70

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

GRAL risks and drawbacks

The deepest 1-year drawdown on record here is 62.9%.

Who may consider GRAL — and who may not

It is a weaker fit for investors who need monthly cash flow (GRAL does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on GRAL

• All tickers starting with G

Tagged: Healthcare.

Frequently asked questions